Eupraxia Pharmaceuticals (EPRX) EPS (Basic) (2023 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly EPS (Basic) of -$0.22 for Q1 2026, down 17.67% year-over-year from -$0.27 in Q1 2025, and up 46.64% quarter-over-quarter from -$0.42 in Q4 2025.
Powered by 
Analysis
Eupraxia Pharmaceuticals (EPRX) EPS (Basic) (2023 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported EPS (Basic) for 4 consecutive years, with -$0.22 the latest figure, recorded in Q1 2026.
- In Q1 2026, EPS (Basic) fell 17.67% year-over-year to -$0.22; the TTM figure through Mar 2026 stood at -$0.78 (down 6.21% YoY), while the FY2025 annual figure was -$0.97, down 27.34% from the prior year.
- EPS (Basic) improved to -$0.22 in Q1 2026 per EPRX's latest filing, from -$0.42 in the prior quarter.
- Across five years, EPS (Basic) topped out at -$0.17 in Q3 2024 and bottomed at -$0.43 in Q2 2023.
- Historically, EPS (Basic) has averaged -$0.24 across 4 years, with a median of -$0.2 in 2023.
- Annual changes were most pronounced in 2024 — EPS (Basic) surged 60.59% — and 2025, when it sank 88.43%.
- Eupraxia Pharmaceuticals' EPS (Basic) stood at -$0.19 in 2023, then retreated by 15.7% to -$0.22 in 2024, then tumbled by 88.43% to -$0.42 in 2025, then jumped by 46.64% to -$0.22 in 2026.
- Business Quant data shows EPRX's EPS (Basic) at -$0.22 in Q1 2026, -$0.42 in Q4 2025, and -$0.17 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 7.70 |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -1.96 |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -3.06 |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 2.12 |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 1.23 |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 0.18 |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -0.06 |
| 10 | Eupraxia Pharmaceuticals | 305.07 Mn | 305.07 Mn | - | -0.36 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.36 |
| Mar 31, 2026 | -0.32 |
| Dec 31, 2025 | -0.42 |
| Sep 30, 2025 | -0.19 |
| Jun 30, 2025 | -0.26 |
| Mar 31, 2025 | -0.20 |
| Dec 31, 2024 | -0.22 |
| Sep 30, 2024 | -0.25 |
| Jun 30, 2024 | -0.25 |
| Mar 31, 2024 | -0.25 |
| Dec 31, 2023 | -0.42 |
| Sep 30, 2023 | -0.24 |
| Jun 30, 2023 | -0.49 |
| Mar 31, 2023 | -0.20 |